Frazier Life Sciences Management as of June 30, 2023
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 48 positions in its portfolio as reported in the June 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Hillevax (HLVX) | 10.0 | $168M | 9.8M | 17.19 | |
Chinook Therapeutics | 10.0 | $167M | 4.3M | 38.42 | |
Phathom Pharmaceuticals (PHAT) | 8.6 | $145M | 10M | 14.32 | |
Newamsterdam Pharma Company Ordinary Shares (NAMS) | 7.7 | $129M | 11M | 11.89 | |
Krystal Biotech (KRYS) | 6.9 | $116M | 990k | 117.40 | |
Mirum Pharmaceuticals (MIRM) | 6.7 | $113M | 4.4M | 25.87 | |
Arcutis Biotherapeutics (ARQT) | 4.9 | $83M | 8.7M | 9.53 | |
Syndax Pharmaceuticals (SNDX) | 4.6 | $78M | 3.7M | 20.93 | |
Verona Pharma Sponsored Ads (VRNA) | 3.7 | $62M | 2.9M | 21.14 | |
Vaxcyte (PCVX) | 3.5 | $58M | 1.2M | 49.94 | |
Rhythm Pharmaceuticals (RYTM) | 2.1 | $36M | 2.2M | 16.49 | |
Bridgebio Pharma (BBIO) | 2.0 | $34M | 2.0M | 17.20 | |
Tarsus Pharmaceuticals (TARS) | 1.9 | $32M | 1.8M | 18.07 | |
Alpine Immune Sciences (ALPN) | 1.8 | $31M | 3.0M | 10.28 | |
Kalvista Pharmaceuticals (KALV) | 1.7 | $29M | 3.2M | 9.00 | |
Disc Medicine (IRON) | 1.7 | $29M | 655k | 44.40 | |
Crinetics Pharmaceuticals In (CRNX) | 1.5 | $26M | 1.4M | 18.02 | |
Revolution Medicines (RVMD) | 1.4 | $23M | 855k | 26.75 | |
Theseus Pharmaceuticals | 1.3 | $21M | 2.2M | 9.33 | |
ACADIA Pharmaceuticals (ACAD) | 1.2 | $21M | 857k | 23.95 | |
Merus N V (MRUS) | 1.2 | $20M | 747k | 26.33 | |
Anaptysbio Inc Common (ANAB) | 1.1 | $18M | 900k | 20.34 | |
Cogent Biosciences (COGT) | 1.1 | $18M | 1.5M | 11.84 | |
Tyra Biosciences (TYRA) | 1.0 | $18M | 1.0M | 17.03 | |
Aerovate Therapeutics (AVTE) | 1.0 | $17M | 995k | 17.15 | |
Enliven Therapeutics (ELVN) | 1.0 | $17M | 831k | 20.41 | |
Oric Pharmaceuticals (ORIC) | 1.0 | $17M | 2.1M | 7.76 | |
Trevi Therapeutics (TRVI) | 1.0 | $16M | 6.9M | 2.39 | |
Morphic Hldg (MORF) | 0.9 | $15M | 266k | 57.33 | |
Cerevel Therapeutics Hldng I (CERE) | 0.7 | $13M | 393k | 31.79 | |
Reata Pharmaceuticals Cl A | 0.6 | $10M | 100k | 101.96 | |
Macrogenics (MGNX) | 0.6 | $9.6M | 1.8M | 5.35 | |
Replimune Group (REPL) | 0.5 | $9.0M | 387k | 23.22 | |
Autolus Therapeutics Spon Ads (AUTL) | 0.5 | $8.9M | 3.7M | 2.38 | |
Prothena Corp SHS (PRTA) | 0.5 | $8.7M | 128k | 68.28 | |
Intellia Therapeutics (NTLA) | 0.5 | $8.3M | 204k | 40.78 | |
Arvinas Ord (ARVN) | 0.4 | $7.1M | 285k | 24.82 | |
Edgewise Therapeutics (EWTX) | 0.3 | $5.8M | 749k | 7.75 | |
Immunovant (IMVT) | 0.3 | $5.7M | 300k | 18.97 | |
Bluebird Bio (BLUE) | 0.3 | $5.6M | 1.7M | 3.29 | |
Deciphera Pharmaceuticals (DCPH) | 0.3 | $5.2M | 370k | 14.08 | |
Silence Therapeutics Ads (SLN) | 0.3 | $4.8M | 881k | 5.50 | |
Gritstone Oncology Ord (GRTS) | 0.3 | $4.7M | 2.4M | 1.95 | |
Sutro Biopharma (STRO) | 0.2 | $3.6M | 780k | 4.65 | |
Adc Therapeutics Sa SHS (ADCT) | 0.2 | $3.5M | 1.6M | 2.15 | |
Aclaris Therapeutics (ACRS) | 0.2 | $2.7M | 264k | 10.37 | |
Passage Bio (PASG) | 0.1 | $1.7M | 1.9M | 0.94 | |
Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.1 | $1.0M | 500k | 2.09 |